Studies with human ovarian cancers have shown that Treg-cells traffick to the tumor mass and ascites via chemokine receptor CCR4 responding to CCL22 released by tumor cells and tumor-associated macrophages (TAMs). This evidence concerns the gene CCL22 and neoplasm.